This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Focetria (with M59 adjuvant)

CSL Limited

Drug Names(s): H1N1 Vaccine (NVS), Foclivia, M59 adjuvanted pandemic flu vaccine

Description: Focetria is a pandemic flu vaccine containing viral surface antigens (haemagglutinin and neuraminidase) and the squalene-based adjuvant M59. Like other pandemic flu vaccines, it followed a regulatory pathway involving the demonstration of an immune response using a mock-up vaccine that employed antigens from an available flu strain (a Vietnamese strain of H5N1 influenza). The currently marketed form was prepared in response to the 2009 swine flu pandemic, and contains antigens from that strain.

Deal Structure: Novartis and CSL
In October 2014, Novartis entered into a definitive agreement to divest its influenza vaccines business to CSL Limited (CSL) for an agreed price of USD 275 million. This transaction requires regulatory approvals and is expected to close in the second half of 2015.

In August 2015, CSL announced that it has closed ts transaction to acquire Novartis global influenza vaccine business for a cash consideration of US$275 million.

Focetria (with M59 adjuvant) News

Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug